ICU Medical, Inc. (NASDAQ:ICUI) Given Consensus Recommendation of "Buy" by Brokerages

Key Points

• ICU Medical, Inc. has received an average recommendation of "Buy" from five research firms, with one strong buy, three buy ratings, and one hold rating.
• The average 12-month target price among analysts for ICU Medical is $179.00, while Raymond James recently lowered its price target from $187.00 to $180.00.
• CEO Vivek Jain significantly increased his stake in ICU Medical by acquiring 21,929 shares at an average cost of $112.84 per share, boosting his ownership by 20.26%.

Shares of ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) have been assigned an average recommendation of "Buy" from the five research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $179.00.

A number of research firms have recently issued reports on ICUI. Wall Street Zen upgraded shares of ICU Medical from a "hold" rating to a "buy" rating in a research note on Friday. Raymond James Financial reduced their target price on shares of ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating for the company in a research note on Friday, August 8th. Finally, Piper Sandler assumed coverage on shares of ICU Medical in a report on Friday, August 15th. They issued an "overweight" rating and a $145.00 price target on the stock.

Insider Activity

In other news, CEO Vivek Jain acquired 21,929 shares of the firm's stock in a transaction dated Thursday, August 14th. The shares were acquired at an average cost of $112.84 per share, with a total value of $2,474,468.36. Following the acquisition, the chief executive officer directly owned 130,149 shares of the company's stock, valued at approximately $14,686,013.16. The trade was a 20.26% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director David C. Greenberg bought 1,200 shares of ICU Medical stock in a transaction on Wednesday, August 27th. The stock was acquired at an average price of $126.42 per share, for a total transaction of $151,704.00. Following the purchase, the director owned 7,960 shares of the company's stock, valued at approximately $1,006,303.20. This trade represents a 17.75% increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.50% of the stock is owned by insiders.

Institutional Investors Weigh In On ICU Medical

Several institutional investors have recently added to or reduced their stakes in ICUI. Cullen Frost Bankers Inc. acquired a new stake in shares of ICU Medical during the second quarter worth about $38,000. GAMMA Investing LLC boosted its stake in ICU Medical by 27.2% during the first quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier's stock worth $99,000 after buying an additional 153 shares during the last quarter. Blue Trust Inc. boosted its stake in ICU Medical by 23.0% during the first quarter. Blue Trust Inc. now owns 801 shares of the medical instruments supplier's stock worth $111,000 after buying an additional 150 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of ICU Medical by 11.6% in the 2nd quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier's stock valued at $128,000 after purchasing an additional 101 shares during the last quarter. Finally, Headlands Technologies LLC purchased a new stake in shares of ICU Medical in the 2nd quarter valued at $177,000. Institutional investors and hedge funds own 96.10% of the company's stock.

ICU Medical Stock Performance

Shares of NASDAQ ICUI opened at $130.58 on Tuesday. The firm's 50-day moving average price is $126.48 and its two-hundred day moving average price is $134.22. The stock has a market capitalization of $3.22 billion, a P/E ratio of -85.91 and a beta of 0.86. The company has a quick ratio of 1.17, a current ratio of 2.44 and a debt-to-equity ratio of 0.63. ICU Medical has a 52-week low of $107.00 and a 52-week high of $196.26.

ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.44 by $0.66. The company had revenue of $543.57 million during the quarter, compared to analyst estimates of $543.33 million. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The company's revenue for the quarter was down 8.0% on a year-over-year basis. During the same quarter last year, the business posted $1.56 EPS. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. As a group, sell-side analysts forecast that ICU Medical will post 4.11 earnings per share for the current year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.